Skip to main content

This Month in Corruption: Improprieties, Deceptions, Misrepresentations

Surgical Device Boosted by Deceptive Marketing. On Dec. 13, AG Healey announced that Massachusetts will receive $2.4 million from a medical device company as part of a multi-state settlement that resolved allegations of unlawfully promoting a device used in certain surgical procedures. 

In a consent judgment entered that day in Suffolk Superior Court, Boston, Medtronic Sofamor Danek, Inc., and Metronic Sofamor Danek USA, Inc., agreed to resolve claims they had engaged in a deceptive marketing strategy for a device intended to stimulate bone growth.
“Companies cannot use deceptive practices to increase their profits, while compromising the safety and well-being of patients,” Healey said.  “With this settlement, we are bringing more than $2 million back to Massachusetts after uncovering this unlawful conduct.”

The payment was part of a $12 million multi-state settlement that also involved Oregon, California, Illinois and Washington.
Benefits of Four Prescription Drugs Misrepresented  On Dec. 20, AG Healey announced that Massachusetts will receive nearly $250,000 from Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) as part of a nationwide settlement to resolve allegations that the company had unlawfully marketed four of its prescription drugs: Micardis, Aggrenox, Atrovent, and Combivent. The payment is part of a $13.5 million multi-state settlement that concluded an investigation by Healey and 50 other attorneys general.

According to a press release from the AG, the states specifically alleged that BIPI misrepresented that its antiplatelet drug, Aggrenox, was effective for many conditions “below the neck,” such as heart attacks and congestive heart failure, and that it was superior to Plavix without evidence to substantiate that claim.  The states also alleged that the company misrepresented that Micardis protected patients from early-morning strokes and heart attacks and treated metabolic syndrome, and misrepresented that Combivent could be used as a first-line treatment for bronchospasms associated with chronic obstructive pulmonary disease (COPD).  BIPI further stood accused of falsely stating that Atrovent and Combivent could be used at doses exceeding the maximum dosage recommendations in the product labelling and that they were essential for treatment of COPD.
“Misrepresenting the benefits of prescription drugs puts people’s health at risk,” said Healey.  “Companies cannot compromise the well-being of patients to make a profit.”

Comments

Post a Comment

Popular posts from this blog

Historical Significance Had Little Heft on the Scale of Progress in Booming Malden

The First Church in Malden, Congregational, a once-cherished emblem of the history of Malden, Massachusetts, was wiped out a few weeks ago for the sake of a new downtown development. The site of the church was contiguous to the Malden Government Center complex (city hall and police headquarters), which had been built in the mid-1970s in the middle of Pleasant Street in an attempt to create a pedestrian shopping mall from that point down to where Pleasant Street spills in to Main Street.   It turned out to be an ill-conceived and ridiculously hopeful project: no mall ever materialized.   For years, the people of Malden yearned to correct that colossal mistake by demolishing the Government Center and reopening the entire length of Pleasant Street to the smooth flow of vehicular traffic.   Enter the Jefferson Apartment Group of Virginia in 2015.   It proposed spending $100 million to demolish the Government Center; replace it with apartments, offices and hundreds of par...
Post a Comment
Read more

Ethics Chief Gets Permanent Appointment; Case Overview Shows Agency's Vital Role

A week ago today, on Feb. 17, the Massachusetts State Ethics Commission announced the appointment of David A. Wilson as its executive director, where he’s responsible for administering and enforcing the state’s conflict of interest and financial disclosure laws. A graduate of Columbia University School of Law and Brandeis University in Waltham, Wilson is kind of a fixture of Massachusetts government, having been an attorney on the Ethics Commission staff for three decades.   For the past eight months, he’d been serving as the commission’s acting executive director.   He needs no warm-up for this big role. The commission is composed of five members, three appointed by the governor and one each appointed by the secretary of state and attorney general.   All of the current commissioners are attorneys, and three of them are retired judges: Barbara Dortch-Okara, Regina Quinlan and David Mills. (The non-judge lawyer-members are Thomas Sartory and Maria Krokidas. Wilson’s appoin...
Post a Comment
Read more

Boston Municipal Research Bureau 'Update' Has Me Thinking Thoughts of PILOTS

I always thought that hospitals and universities owned most of the tax-exempt land in the City of Boston.   Boy was I mistaken. The total area of Boston consists of 47.84 square miles.   Of that total, 49 percent, or 23.44 square miles is tax-exempt.   And of those 23.44 tax-exempt square miles, only 4.98 square miles are owned by institutions devoted to medicine and health care, higher education, cultural pursuits and worship (churches, synagogues, mosques), etc.   The rest is mainly owned by the government. I got this information from the latest (10-3-17) “Bureau Update” from the Boston Municipal Research Bureau, an independent organization that’s been keeping tabs on Boston’s finances since 1932.   Thank you, BMRB. Here are some other things I gleaned: The state government owns 48.5% of all the tax-exempt land in the city. The city and federal governments own, respectively, 28.6%  and 1.6% of all the tax-exempt land. The total assessed value of al...
Post a Comment
Read more